Status:
COMPLETED
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Lead Sponsor:
Eli Lilly and Company
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.
Eligibility Criteria
Inclusion
- Healthy men and non-childbearing potential women
- Body mass index between 18.0-32.0 kilograms per square meter (kg/m\^2)
- Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies
Exclusion
- Taking over-the-counter or prescription medication with the exception of vitamins or minerals
- Smoke more than 10 cigarettes per day
- Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01227252
Start Date
December 1 2010
End Date
April 1 2011
Last Update
July 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Glendale, California, United States, 91206